| Document |
Document Title |
|
WO/2020/226526A1 |
The invention relates to the field of medicine, particularly to a method for increasing blood haemoglobin level in a cancer patient. A method for increasing blood haemoglobin level in a cancer patient, wherein a pharmaceutical composi...
|
|
WO/2020/227637A1 |
The present disclosure provides methods and compositions for generating populations of auxotrophic cells and populations of differentiated cells and selecting populations of transfected cells using split auxotrophy.
|
|
WO/2020/227162A1 |
Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs), e.g., Factor VIII (FVIII) including PEGylated and other forms of stabilized FVIII, within the GI tract. Many em...
|
|
WO/2020/227314A1 |
Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
|
|
WO/2020/226907A1 |
The present invention relates to single domain antibodies (sdAbs) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1) molecules that are present on activated platelets at the site of an injury, and es...
|
|
WO/2020/223436A1 |
Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, i...
|
|
WO/2020/221291A1 |
The present invention relates to a method for treating hemoglobinopathy in an individual, comprising: (a) an evaluation step: the evaluation step comprises evaluating the ability of a first population of modified CD34-positive hematopoie...
|
|
WO/2020/222302A1 |
The present invention relates to a pharmaceutical composition that is used for treating or preventing acidosis of chronic kidney disease with anemia and contains citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate t...
|
|
WO/2020/221309A1 |
Provided is a small activating nucleic acid molecule which increases HMBS gene expression, and an application thereof. The small activating nucleic acid molecule is a double-stranded or single-stranded RNA molecule targeting the HMBS gen...
|
|
WO/2020/215999A1 |
Use of trifluridine or a trifluridine tipiracil composition in the preparation of a medicament for treating blood diseases. Specifically involved is use in the preparation of a medicament for treating blood diseases caused by a β-hemogl...
|
|
WO/2020/217567A1 |
The present invention provides a hydrogen gas dissolution method for dissolving hydrogen gas in a liquid contained in a flexible container capable of expanding and shrinking, the method including: causing a bottle needle to penetrate thr...
|
|
WO/2020/219384A1 |
The present disclosure provides an apixaban transdermal patch for treatment of thrombosis and related disorders. The transdermal patch may be administered on a daily basis or a period of 2 days, 3 days, 4 days, 5 days, 6 days or 7 days. ...
|
|
WO/2020/219964A1 |
The disclosure provides compositions and methods useful for the depletion of a specific population of endogenous hematopoietic stem cells and/or immune cells from a subject prior to transplantation with genetically modified stem cells to...
|
|
WO/2020/218829A1 |
The present invention relates to a flagellin fusion protein and a use thereof and, more specifically, to a fusion protein comprising: flagellin, a fragment thereof, or a variant thereof; and an immunoglobulin Fc region, and a use in whic...
|
|
WO/2020/215895A1 |
The present invention relates to the technical field of medicine, and relates to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of ginkgolide B by means of a hydroxyl ...
|
|
WO/2020/219557A1 |
The present disclosure provides compositions comprising a magnetic probe and a live or inert platelet cell or platelet mimicking system, and methods of using the same.
|
|
WO/2020/219845A1 |
The present disclosure provides improved genome editing compositions and methods for editing a human Wiskott-Aldrich syndrome gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at ...
|
|
WO/2020/214929A1 |
Provided herein are formulations comprising recombinant AAV particles. In some embodiments, the formulation is a frozen formulation or a lyophilized formulation. Also provided herein are methods for reducing rAAV genome release from rAAV...
|
|
WO/2020/211009A1 |
Disclosed is a therapeutic use of an extract from rabbit skin inflamed by vaccinia virus. Particularly, disclosed is a use of an extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage or pancytopenia ...
|
|
WO/2020/211751A1 |
The compound shown in formula I, and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof. The compound shown in formula...
|
|
WO/2020/211674A1 |
The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing ...
|
|
WO/2020/213012A1 |
The present disclosure provides a composition comprising: a polyanionic component comprising casein or derivatives thereof; and a polycationic component comprising chitosan or derivatives thereof, wherein the composition is in the form o...
|
|
WO/2020/215091A1 |
Disclosed herein are compositions, methods, and systems useful in the prevention, management, or treatment of various conditions associated the lymphatic vasculature, including, but not limited to lymphedema. The disclosed methods and co...
|
|
WO/2020/210087A1 |
The present invention relates to rusalatide acetate compositions, formulations and dosage forms that include 23 amino acid monomer ("Monomer"), dimer ("Dimer") of two 23 amino acid Monomers, or any combination of Monomer and Dimer, where...
|
|
WO/2020/209285A1 |
Developed were: a nucleic acid complex that exhibits an excellent anti-sense effect in skeletal muscle and/or cardiac muscle; and a therapeutic or prophylactic composition that contains said nucleic acid complex as the active ingredient,...
|
|
WO/2020/210339A1 |
The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amou...
|
|
WO/2020/207355A1 |
Provided is a pharmaceutical composition for treating refractory hypertension. The pharmaceutical composition consists of amlodipine, chlorthalidone, and amiloride. The provided pharmaceutical composition provides an effective antihypert...
|
|
WO/2020/209059A1 |
This disclosure provides a pharmaceutical composition for treating hyperammonemia that contains α-ketoglutaric acid or dimethyl-α-ketoglutaric acid, or a pharmaceutically acceptable salt thereof.
|
|
WO/2020/210629A1 |
This invention relates to solid amorphous Compound (I) having the formula (I) and to solid amorphous dispersions comprising Compound (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solv...
|
|
WO/2020/210067A1 |
Chimeric antigen receptors (CARs) specific to DLL3, vectors encoding the DLL3 CAR, recombinant host cells comprising the DLL3 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expr...
|
|
WO/2020/209752A1 |
An emulsion comprises a perfluorocarbon compound perfluorodecalin and a perfluorocarbon additive and phospholipids in the form of liposomes (vesicles) prepared by homogenization under pressure in an aqueous saline medium. The perfluoroca...
|
|
WO/2020/210643A1 |
Methods of treating and preventing cancer, comprising administering a therapeutically effective amount of cell membrane permeability restoring therapy are provided herein.
|
|
WO/2020/205838A1 |
Described herein are methods and compositions for treating a beta-thalassemia.
|
|
WO/2020/199671A1 |
Provided is an immune cell formulation for effectively improving bone marrow hematopoietic microenvironment. The preparation of said cell formulation comprises the following steps: separating blood cells from blood; culturing the blood c...
|
|
WO/2020/201305A1 |
The invention relates to novel compounds of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as iron chelators, more particularly for the use in the prophyl...
|
|
WO/2020/204152A1 |
The present invention addresses the problem of providing a new drug for preventing, suppressing advance of symptoms, suppressing recurrence, or treating autoimmune disease. As a result of diligent studies, the inventors of the present ...
|
|
WO/2020/203086A1 |
[Problem] To provide an improved glucose-containing peritoneal dialysate, ophthalmic composition, or infusion that is not only capable of, as a result of simply being blended, suppressing an increase in the blood glucose level even when ...
|
|
WO/2020/205683A1 |
In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL...
|
|
WO/2020/198054A1 |
This disclosure generally relates to treating anemias. More specifically, the disclosure relates to use of muscarinic acetylcholine receptor subtype 4 antagonists, such as small molecule compounds, to promote self-renewal of burst formin...
|
|
WO/2020/198691A1 |
Disclosed herein are potency assays for a gene therapy treatment for β-thalassemia. Also disclosed herein are methods for measuring relative potency of a drug product.
|
|
WO/2020/198367A1 |
Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β -thala...
|
|
WO/2020/196381A1 |
An objective of the present invention is to provide an infusion of improved subcutaneous diffusivity. Bicarbonate ions are included in the infusion for subcutaneous administration to improve the subcutaneous diffusivity of the infusion f...
|
|
WO/2020/194225A1 |
Mixture containing lactoferrin, sodium citrate and sodium bicarbonate and whose molar ratio intended as moles of lactoferrin/ (moles of sodium citrate+ moles of sodium bicarbonate) is between 10"4 and 10"3 for use in the treatment of inf...
|
|
WO/2020/198323A1 |
The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
|
|
WO/2020/191441A1 |
The present invention relates to compositions and methods for the treatment and prevention of thrombogenic-related diseases and disorders. The compositions may comprise antigen-binding fragments that prevent platelet activation by either...
|
|
WO/2020/197330A1 |
The present invention relates to: a composition for correcting inversions by targeting a non-inverted gene and a distal-inverted gene and restoring same, and a composition for treating hemophilia; and a gene scissor system (CRISPR/Cas sy...
|
|
WO/2020/190172A1 |
The present preparation contains food-grade gelatine, an antibiotic and bovine blood plasma in the following proportions by weight: 1.0 wt% kanamycin monosulfate, 3.0% bovine blood plasma and the remainder being food-grade gelatine. The ...
|
|
WO/2020/191362A1 |
Disclosed herein are potency assays for a gene therapy treatment for sickle cell disease. Also disclosed herein are methods for measuring relative potency of a drug product used for the treatment of sickle cell disease.
|
|
WO/2020/188836A1 |
The present invention addresses the problem of providing an anti-podoplanin antibody which is a humanized antibody or a mouse-human chimeric antibody, or an antibody fragment containing an antigen binding domain of the anti-podoplanin an...
|
|
WO/2020/187123A1 |
Disclosed are a pyrrole amidopyridone represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereomer, a tautomer, a solvate, a polymorph, or a prodrug thereof, a preparation method there...
|
